Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03496779 | Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine | completed | Phase 2 | 71 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 30, 2025 | clinicaltrials |
| NCT03548207 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma(CARTITUDE-1) | completed | Phase 1 / Phase 2 | 126 | Janssen Research & Development, LLCINDUSTRY |
| 2 |
| Jul 30, 2025 |
| clinicaltrials |
| NCT01864018 | Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | completed | Phase 1 / Phase 2 | 87 | Mayo ClinicOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT00878254 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | 25 | University of MiamiOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT02956382 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT02329080 | New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | completed | Phase 2 | 79 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jul 8, 2025 | clinicaltrials |
| NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06511869 | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) | completed | Phase 2 | 48 | Dizal PharmaceuticalsINDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03133221 | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | completed | Phase 2 | 17 | University of Maryland, BaltimoreOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT02765854 | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement | completed | Phase 2 | 70 | Emory UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT01995669 | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT03713294 | Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma | completed | Phase 2 | 37 | Mayo ClinicOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 348 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2025 | clinicaltrials |
| NCT02750670 | Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT00001379 | Treatment and Natural History Study of Lymphomatoid Granulomatosis | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2025 | clinicaltrials |
| NCT02871219 | Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT00112827 | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | City of Hope Medical CenterOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05008224 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)(KEYNOTE-C11) | completed | Phase 2 | 146 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Jun 6, 2025 | clinicaltrials |
| NCT03012880 | Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03490344 | Short Course Daratumumab in Patients With Multiple Myeloma | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04062448 | A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) | completed | Phase 2 | 16 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT03113422 | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy(PrE0403) | completed | Phase 2 | 56 | PrECOG, LLC.OTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03361748 | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma(KarMMa) | completed | Phase 2 | 149 | CelgeneINDUSTRY | 8 | May 23, 2025 | clinicaltrials |
| NCT04689659 | Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma | completed | Phase 2 | 55 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT01350245 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | completed | Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04176380 | RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma | completed | Phase 2 | 15 | Rapa Therapeutics LLCINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT03583424 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05149378 | Venetoclax Based Regimen for R/R T-ALL | completed | Phase 2 | 25 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT00179673 | Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 43 | CelgeneINDUSTRY | 2 | May 13, 2025 | clinicaltrials |
| NCT04402138 | Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | completed | Phase 2 | 15 | SCRI Development Innovations, LLCOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT01729091 | Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT03417284 | Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT00135200 | Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma | completed | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01458366 | Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide | completed | Phase 1 / Phase 2 | 38 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT02224729 | Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03412565 | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | completed | Phase 2 | 265 | Janssen Research & Development, LLCINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT05347485 | A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma | completed | Phase 2 | 86 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT02566304 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 35 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03860038 | TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 113 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Apr 24, 2025 | clinicaltrials |
| NCT04849351 | Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma | completed | Phase 2 | 178 | Hutchison Medipharma LimitedINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03004833 | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma(NIVAHL) | completed | Phase 2 | 110 | University of CologneOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03700450 | Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma | completed | Phase 2 | 37 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03442673 | Chemotherapy and G-CSF for Mobilization(MOCCCA) | completed | Phase 2 | 137 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02744612 | Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 39 | City of Hope Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04939844 | REST - Replacing Steroids in the Transplant Ineligble(REST) | completed | Phase 2 | 51 | Oslo University HospitalOTHER | 2 | Mar 20, 2025 | clinicaltrials |
| NCT02506959 | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT02631746 | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Mar 14, 2025 | clinicaltrials |
| NCT02924272 | Ixazomib Rollover Study | completed | Phase 2 | 32 | TakedaINDUSTRY | 11 | Mar 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 30, 2025source: clinicaltrials